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ABSTRACT 
Osteocalcin and osteopontin are noncollagenous proteins secreted by 
osteoblasts and regulated by a complex interplay of systemic and locally 
produced factors, including growth factors and steroid hormones. We 
investigated the mechanism by which transforming growth factor-p 
(TGFP) inhibits 1,25-dihydroxyvitamin D, (1,25-(OH),D,)-enhanced ex- 
pression of the osteocalcin (OC) and osteopontin (OP) genes. ROS 17/2.8 
cells, in which both genes are expressed, were transfected with reporter 
constructs driven by native (i.e. wild-type) rat OC and mouse OP pro- 
moters. TGFp abrogated the 1,25-(OH),D, enhanced transcription of 
both the OC and OP genes. The inhibitory TGFp response for each 
requires vitamin D response element (VDRE) sequences, although there 
are additional contributions from proximal basal regulatory elements. 
These transcriptional effects were further investigated for contribution 
of the trans-activating factors, which interact with OC and OP VDREs, 
involving the vitamin D receptor (VDR) and retinoid X receptor (RXR). 
Gel mobility shiR assays show that TGFp significantly reduces induction 
of the heterodimeric VDR/RXR complexes in 1,25-(OH),D,,-treated ROS 
17/2.8 cells. However, Western blot and ligand binding analyses reveal 
that TGFp does not affect nuclear availability of the VDR. We also show 
that activator protein-l activity is up-regulated by TGFP; thus, activator 
protein-l binding sites in the OC promoter may potentially contribute to 
inhibitory effects of TGFp on basal transcription. Our studies demon- 
strate that the inhibitory action of TGFB on the 1,25-(OH),D,, enhance- 
ment of OC and OP transcription in osteoblastic cells results from mod- 
ulations of protein-DNA interactions at the OC and OP VDRE, which 
cannot be accounted for by changes in VDR protein levels. As OC and OP 
participate in bone turnover, our results provide insight into the con- 
tributions of TGFp and 1,25-(OH),D:, to VDR-mediated gene regulatory 
mechanisms operative in bone formation and/or resorption events. (En- 
docrinology 137: 2001-2011, 1996) 
0 STEOCALCIN (OC) and osteopontin (OP) are two ma- jor noncollagenous calcium binding proteins in bone (1). 
During development of the osteoblast phenotype, osteopontin 
is expressed during the period of active proliferation and de- 
creases postproliferatively, and expression is up-regulated in 
mature osteoblasts. In contrast, osteocalcin is expressed only 
postproliferatively in mature osteoblasts with the onset of ex- 
tracellular matrix mineralization (2). In ROS 17/2.8 osteosar- 
coma cells, however, both osteocalcin and osteopontin are con- 
stitutively expressed. Some evidence points to the involvement 
of both proteins in bone turnover; for example, both proteins 
bind to hydroxyapatite and are regulated by 1,25-(OH),D, and 
TGFP. In addition, osteocalcin contributes to recruitment 
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and/or differentiation of osteoclasts (3-5), and osteopontin ap- 
pears to be important for attachment of the osteoclasts to the 
bone matrix (6, 7). 
TGFP and 1,25-(OH),D, are involved in regulation of both 
bone formation and resorption. The steroid hormone 1,25- 
(OH),D, plays a principle role in calcium homeostasis and 
skeletal metabolism (S), as well as influences expression of 
genes related to establishment and maintenance of the bone 
cell phenotype (9). 1,25-(OH&D, exerts its primary effect by 
binding to its nuclear receptor, the vitamin D receptor (VDR), 
which belongs to the steroid / retinoid / thyroid hormone re- 
ceptor superfamily (10) and acts via binding to distinct vi- 
tamin D response elements (VDRE). VDREs have been iden- 
tified in several genes related to osteoblastic differentiation 
and function: human osteocalcin (11, 12), rat osteocalcin (13- 
15), mouse osteopontin (16), rat 25-hydroxy- and 1,25-dihy- 
droxyvitamin D, 24hydroxylase (17-20), calbindin D28k 
(21), and & integrin (22). 
TGFP is locally produced in bone by osteoblasts and oste- 
oclasts and represents a member of the TGFP / BMP superfam- 
ily of polypeptide hormones, which play key roles in skeletal 
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development and bone remodeling (23,24). In mammals, three 
isoforms of TGFP have been identified: TGFP,, TGFP,, and 
TGFP, (25,26). TGFP is present as a latent complex in bone and 
released from the extracellular matrix in an active form during 
bone resorption by osteoclasts (27). TGFP modulates the ex- 
pression of several markers of the osteoblast phenotype (28-35). 
Recent studies suggest that regulation of bone metabolism by 
1,25-(OH),D, and TGFP is functionally coupled. For example, 
combined treatment with TGF/3 and 1,25-(OH&D, of both hu- 
man and rat osteoblast-like cells has been shown to affect pa- 
rameters of osteoblastic differentiation and function (36-38). 
However, the mechanisms by which TGFP and 1,25-(OH),D, 
together modulate the expression of osteoblast-related genes 
remains to be established. In this study, we examined the an- 
tagonistic effects of TGFP, and TGFB, on the 1,25-(OH),D, 
enhancement of osteocalcin and osteopontin gene transcription. 
We show that TGFP inhibition of 1,25-(OH),D, stimulated tran- 
scription involves the selective down-regulation of VDR/RXR 
interactions with both the OC and OP VDREs. 
Materials and Methods 
Cell culture 
ROS 1712.8 osteosarcoma cells, kindly provided by Dr. G. Rodan and 
Dr. S. Rodan (Merck Sharp & Dohme Research Laboratories, West Point, 
PA) lvcr~‘ maintained in Ham’s F12 medium supplemented with 2 mM 
qlutamine, 100 lU/ml penicillin, 100 pg/ml streptomycin, and 5% FCS 
at 37 C under 95% sir/5% CO,. For the experiments, cells were seeded 
in 100 x 20-mm plastic dishes at 0.7 x 10” cells/plate in Ham’s F12 
medium containing 5% FCS and cultured for 24 h. Subsequently, me- 
dium was replaced by Ham’s F12 rvith 2% charcoal-treated FCS, and 
cells were cultured overnight and then incubated for 21 h with 10 ’ M 
1,25-(OH)2D1 and/or 2.5 rig/ml of either TGFP, orTGF&. 1,25-(OH)1D, 
was kindly provided by Dr. M. Uskokolric, Hoffman-La Rochc Inc. 
(Nutley, NJ). TCFP, was purchased from R&D Systems (Minneapolis, 
MN). TGF& was kindly provided by Dr. J. Feyen, Sandoz Pharma Ltd. 
(Bawl, Switzerland). Medium was analyzed for osteocalcin by RIA as 
previously described (39). 
Gel mobility shift assay 
Nuclear extracts were prcparcd as previously described (40). In brief, 
cells were scraped in PBS, and after centrifugation the cell pellet was 
reconstituted in a hypotonic lysis buffer (10 mM HEPES, pH 7.5, 10 mM 
KCI, and 0.2 rnM EDTA) supplemented with 0.75 rnM spermidine, 0.15 
rn,v spcrmine, 1 mu EGTA, 1 rnM dithiothreitol, and a broad spectrum 
of protease inhibitors: 0.2 mM PMSF, 70 pg/ ml N-tosyl-L-phenylalanine 
chloromethyl ketone, 10 g/ml trvpsin inhlbitor, 0.5 pg/ml lcupeptin, 
and 1 .O pg/ ml pepstatin. Then O.& Nonidet I’40 was added, and cells 
were lysed using a dounce homogenizer. After centrifugation, nuclear 
extracts were obtained by incubating nuclei in a hypertonic nuclear 
extraction buffer (20 mM HEPES, pH 7.5, 420 mM KCI, 25% glycerol and 
0.2 mM EDTA) supplemented with the same reagents previously men- 
tioned for the hypotonic Iysis buffer. Desalting was performed by di- 
lution with hypertonic nuclear extraction buffer without KCI. 
For gel mobility shift assays, the following oligonucleotides were 
synthesized: rat osteocnlcin VDRE (14): S’-CTGCACTGGGTGAATGAG- 
GACATTACTGA-3’; mouse ostcopontin VDRE (16): 5’.ACAAGGT- 
TCACCAGGTTCACGTCT-3’; metallothioncin II/activator protein-l 
(AP-1) consensus: 5’.AATTCCTGACTCAGCGCGCG-3’; transcription 
factor Sl’-I const'ns~~s: 5’.CGGATGGGCGGGGCCGGGGATGGCCGGGCGG- 
GGCCGG-3’. 
Gel-purified oligonucleotides were radiolabeled with [y”P] ATP as de- 
scribed previously (41). Protein/DNA binding reactions were performed 
by combining 10 ~1 of a 5 fig protein mixture in a final KC1 concentration 
of 100 mM with 10 ~1 of a DNA mixture containing 1 fmoli ~1 DNA, 0.2 
p*g/p*l nonspecific competitor DNA, poly(dI-dCp(dI-dC) and 2 mhl di- 
thiothreitol for 15 min. Protein/DNA complexes were separated in a 4% 
polyacrylamide gel (acrylamide:bisacrylamide = 8O:l) in 0.5 X TBE elec- 
trophoresis buffer (89 rnM Tris, 89 mFrr borate, 2 mM EDTA, pH 8.4). Gels 
were dried and exposed to x-ray film. 
Transient transfection assay 
The OC-chloramphenicol acetyltransferase (CAT) chimeric reporter 
gene constructs pOCZCAT and Rs/IICAT contain the osteocalcin pro- 
moter sequences -1097/+23 and -3481 +23, rcspectl\rely (42). The OP 
CAT chimeric reporter gene constructs pOP772CAT and pOPS52CAT 
span nucleotides -772/+40 and -552/+41, respectively (16). The 
(VDRE),-tk-luciferasc chimeric reporter gene construct, \vhich \vas gen- 
erously provided by Dr. L. J, Sturzenbecker (Hoffman-La Roche), con- 
tains three copies of the rat osteocalcin VDRE fused to thymidinc kinase 
luciferase. Diethylaminoethyl-dextran-mediated transfections (13) were 
performed with cells plated at a density of 0.8 x 10’ per well in six-v,4 
plates. CAT reporter gene constructs (5 pg) \verc cotransfected with 2 
pg Rous sarcoma virus-luciferase plasmid or pSV2CAT (used as an 
internal control for transfection efficiency) 18 h after plating. After trans- 
fection, cells were fed with Ham’s F12 medium supplemented with 5% 
FCS. Subsequently, 1 h after feeding, cells were incubated \vith TGFfi,, 
TGFP, and / or 1 ,25-(OH)1D,1 in Ham’s F12 with 2% charcoal-treated FCS. 
Cells were har\,estcd after incubation for 24 h, and CAT acti\,ity was 
determined (43). CAT and luciferase assays were normalized on the 
basis of lucifcrase activity and CAT activity, respectively, as well as 
protein content bv Bradford assay (Pierce). Quantitation !vas performed 
by using a fi-emi&ion analyzer (Betascope 603 Betngcn, Waltham, MA). 
Northern blot analysis 
RNA isolation, clectrophoresls of total RNA (10 pg) in formaldehyde 
gels, Northern blotting [Zetaprobe membranes (Bio-Rnd, Melville, NY)], 
prchybridizations, and hybridizations were performed as described pre- 
viously (43). The sources of the following probes used for hybridi/.ation 
arc described by Shalhoub c’t rll. (14): ostrocalcin, osteopontin, histone 
H4, collagen t>;pe I, a lkalinc phosphatase, and vitamin D receptor 
probes. Values tor mRNA Ivere normalized to GAPDH and ribosomal 
2% transcripts. For reh\bricli/.ation, filters wcrc \\,ashed for 2 h at 65 C 
with 5 mu Tris (pH 8.0), 0.2 rnhl EDTA (pH t;.O), 0.05”6 wdium pyre- 
phosphate, and 0.1 X Denhardt’s solution. 
Western blot analysis 
Nuclear proteins were separated in 12% SDS-PAGE gels (acrylamide: 
bisacrylamide = 3O:l) (13) and transferred to Z&probe membrane 
follobved bv Western blot analysis (ECL, Amersham Life Sciences, Ar- 
lington Heights, IL). In brief, 5% blocking agent was used in PBS COP 
taining 0.1% Tween-20. The blot was subsequently incubated with VDR 
antibody (IVGRCI 1) in a 1:lOOO dilution and incubated Ltith the second 
antibody (peroxidase antimouse antibody at a l:lO,OOO dilution). 
Preparations of cell extracts and I’H]1,25-(OHI,D,., binding 
assay 
Vitamin D ligand binding assays \yere performed as described h\ 
Pals c*t (71. (3.5). In brief, after incubation \vith TGFfl and /or 1,25- 
(OH),D;, cells wcrc washed with 2% BSA in serum-free medium for 
2 h to remove residual unlabeled 1,25-(OH)1D,. Then cells were 
extracted on ice in a hypertonic buffer consisting of 300 rnc~ KCI, 10 
mhr Tris-HCI (pH 7.1), 1 mM EDTA, 5 rn,v dithiothwtol, 10 mhl 
sodium molybdate, and 0.1% Triton X-100. High-speed supernatants 
Lvere obtained, and 250 ~1 aliquots were incubated o\,ernight at 1 C 
for single point assays with 0.25 IBM [‘H]1,25-(OH)ZD, in the absence 
or presence of a 200-fold molar excess of unlabelled hormone. After 
removal of unbound ligand, receptor-bound vitamin D was quanti- 
tated by liquid scintillation counting. 
Data analysis 
To assess significance of the interaction bettveen t\vo agents, tested 
data were analyzed with analysis of variance (ANOVA) for t\vo-\va\ 
design (indicated by #). Other statistical analyses jvere performed using 
Student’s t test (indicated by ‘). 
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FIG. 1. TGFp and/or 1,25-(OH),D, af- 
fect the expression of mRNAs related to 
osteoblast function and differentiation. 
Cells were cultured as described in Mu- 
terials and Methods and incubated for 
24 h with 2.5 rig/ml TGF6, (T,), 2.5 
rig/ml TGFP, (T,), and/or 10-s M 1,25- 
(OH),D, (D) or vehicle (C). Northern 
blots were hybridized with the following 
probes: osteocalcin (OC), osteopontin 
(OP), histone H4 (H4), alkaline phos- 
phatase (AP), collagen type I (COLL I), 
vitamin D receptor (VDR), glyceralde- 
hyde 6-phosphate dehydrogenase 
(GAPDH), and LS6 (2% ribosomal 
RNA). A, Composite autoradiograms 
from representative experiments. B, 
Bar graphs (arbitrary absorbance 
units, A.U.) of OC, OP, VDR and 28s 
represent quantitation of mRNA levels 
by densitometric scanning of the auto- 
radiogram. OC, OP, and VDR mRNA 
levels are normalized for 28s. Similar 
results were obtained in multiple inde- 
pendent experiments. *, P < 0.05; **, 
P < 0.001 us. control; #, P < 0.05; ##, 
P < 0.01; ##, P < 0.005 (by ANOVA). 
For details of P value calculation, see 
Materials and Methods. 
Results effects of both TGFPl and TGFP2 on basal osteocalcin gene 
Effects of TGFP,, TGF&+ and 1,25-(OH)$, influence 
expression of genes related to osteoblast function and 
differentiation 
expression (Fig. 1). Steady-state mRNA levels of osteopontin 
were not affected by either growth factor after 24 h of treat- 
ment. The 24-h time point was selected for our studies as this 
treatment interval facilitates assessment of the combined ef- 
A 
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As osteoblasts are responsive to TGFP, and TGF& and fects of TGF-/3 and 1,25-(OH),D, on OC and OP gene ex- 
display three classes of TGFP receptors (46), we explored pression. We have previously established that under our 
possible differential effects of these two major isoforms experimental conditions, 1,25-(OH),D, enhancement of OC 
present in bone. Northern blot analysis reveals inhibitory gene expression is maximal at 24 h after administration of the 
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ligand (9). Also, although TGFP modulates parameters of 
1,25-(OH),D,- mediated gene expression as a component of 
an earlier response (i.r. 6 h), significant effects of TGFP on OC 
gene expression are not observed until the 24-h time point 
(37). 
The combined effects of TGFP and 1,25-(OH&D, on OC 
and OP gene expression are also shown in Fig. 1. Both OC 
and OP mRNA levels were increased 6- to lo-fold after 24 h 
of 1,25-(OH)?D, treatment. Both TGFP, and TGFP, inhibited 
the 1,25-(OH)zD,-induced increases in OC or OP expression. 
However, the magnitude of the decrease was reproducibly 
greater for osteocalcin in multiple experiments, consistent 
with the influence of TGFP on basal level of OC gene ex- 
pression. For 1,25-(OH),D,-treated cells, the level of secreted 
OC in the medium, which reflects OC protein synthesis, 
parallels the changes in OC gene expression (Table 1). For 
comparison, TGFP and 1,25-(OH),D, effects on other bone- 
related proteins (r.8. alkaline phosphatase, collagen type 1, 
and vitamin D receptor) and cell proliferation marker (his- 
tone H4) were determined. These genes display different 
patterns of expression after TGFP and 1,25-(OH),D, treat- 
ment, demonstrating the selective responsiveness of the OC 
and OP genes to these factors. 
Effects of combined treatment with TGF/3 and 1,25-(OHizD, 
on OC and OP transcription 
1,25-(OH),D, regulates OC and OP gene expression by 
specific interactions of VDR containing transcription factor 
complexes with defined VDREs in the promoters of both 
genes. To gain insight into the mechanism by which TGFP 
inhibits 1,25-(OH)?D, enhancement of OC and OF’ gene ex- 
pression, we performed transient transfections assays in ROS 
17/2.8 cells with OC and OP promoter CAT fusion constructs 
in the presence of TGFP and/or 1,25-(OH)?D,. After trans- 
fection with an OC promoter construct of 1100 nucleotides, 
which contains the VDRE (pOCZCAT; Fig. 2A), we observed 
a 4- to 6-fold decrease in basal CAT activity in response to 
both TGFP, and TGFP,. 1,25-(OH)zD, increased basal CAT 
activity &fold in 24 h. This increase was inhibited 20- to 
30-fold after coincubation with either TGFP, or TGFP,. Thus, 
in addition to a significant inhibition of basal transcription, 
both TGFP subtypes abrogated 1,25-(OH),D, enhanced OC 
transcription. 
To ascertain the extent to which TGFP effects on OC de- 
pend on VDRE sequences, ROS 17/2.8 cells were transfected 
with a construct in which the VDRE was deleted (pB$ICAT; 
Fig. 28). As expected, the construct did not respond to 1,25- 
(OH),D,. TGFP, or TGFP, either alone or in the presence of 
1,25-(OH),D, caused a 4- to 6-fold decrease in CAT activity. 
This inhibitory effect of TGFP on basal OC gene transcription 
TABLE 1. Effect of either TGFP, or TGFP, and 1,25(OH),D, on 
osteocalcin secretion in medium of ROS 17/2.8 cells (rig/ml) 
Control TGW, TGF& 
control 2.76 -+ 0.23 2.13 -t 0.44 2.26 -t 0.40 
1,25(OH),D:, 15.45 k 2.15 3.44 + 0.35 3.14 i 0.08 
Cells were cultured as described (Materials rind Methods) and 
incubated for 24 h with 2.5 ngiml TGFP,, 2.5 rig/ml TGFP,, and/or 
10 ’ RI 1,25(OH),D:,. Data are expressed as mean + SD. 
is consistent with the presence of a TGFP response element 
in the proximal promoter (47). Notably, the fold decrease 
resulting from coincubation of TGFP and 1,25-(OH),D, was 
significantly less for the OC promoter CAT construct lacking 
the VDRE (4- to 6-fold; pB$IICAT) as compared with the 
OC CAT construct containing the VDRE (20- to 30-fold; 
pOCZCAT). To assess the promoter selectivity of TGFP ef- 
fects on transcription of bone-related genes, we performed 
similar experiments with CAT reporter gene constructs fused 
to the SV40 promoter (pSV2CAT) or lacking a promoter 
(pSVOCAT). TGFP h as only modest inhibitory effects on the 
virally derived SV40 promoter (1.3-fold; data not shown). 
Similar to results with the OC promoter, transfection with 
the osteopontin promoter construct pOP772CAT (Fig. 3A), 
containing 772 nucleotides of 5’ flanking sequences, showed 
a decrease in basal CAT activity after incubation with either 
TGFP, or TGFP, (2-fold). 1,25-(OH)2D.3 caused an 11-fold 
increase in CAT activity, which was inhibited 7-fold by 
TGFP, and TGFP,. The Ol’ construct lacking the VDRE 
(pOP552CAT; Fig. 3B) does not respond to 1,25-(OH),D,. We 
noted that a modest level of TGFP inhibition (2-fold) of OP 
basal promoter activity persists. Taken together, our results 
suggest that TGFP exerts a major effect on 1,25-(OH),D,- 
mediated OC and OP transcription and requires a VDRE 
containing promoter segment. 
To investigate directly the effect of TGFP and 1,25-(OH),D, 
on VDRE-mediated transcription, we transfected cells with 
the (VDRE),-tk-luciferase reporter gene construct, which 
contains three copies of the rat OC VDRE (Fig. 4). Treatment 
with 1,25-(OH),D, increased basal luciferase activity approx- 
imately 4-fold in 24 h. This increase was inhibited 50% and 
30% by TGFP, and TGFP,, respectively, indicating that the 
inhibitory effect of TGFP on 1,25-(OH),D, enhancement of 
OC transcription is at least partly mediated by the VDRE. 
TGFP and l,25-(OH)-,D,.j modulate protein IDNA 
interactions at VDREs 
To address directly the mechanism by which TGF/3 abro- 
gates 1,25-(OH),D,-dependent enhancement of OC and OP 
transcription, we examined protein/DNA interactions at 
VDREs. Gel shift assays were performed with nuclear pro- 
teins from ROS 17/2.8 cells treated with TGFP and/or 1,25- 
(OH)?D3, using labeled OC and OP VDRE oligonucleotides. 
Fig. 5 shows the well established induction of the VDR con- 
taining complexes at both OC and OP VDREs after treatment 
of ROS 17/2.8 cells with 1,25-(OH),D, (16, 40, 48-50). Nu- 
clear proteins from control or TGFP,-treated cells do not 
show VDRE protein / DNA interactions. However, combined 
treatment of 1,25-(OH)>D, with TGFP caused a significant 
reduction of the VDR containing complex at both the OC and 
OP VDREs. Similar reductions in VDRE complexes were 
observed in TGFP,-treated cells (data not shown). This in- 
dicates that the inhibitory effects by TGFP, and TGFP, on the 
1,25-(OH),D,-induced increase in OC and OP transcription 
are at least in part due to decreased binding of transcription 
factors to the VDRE. 
Because both TGFP and 1,25-(OH),D, modulate expres- 
sion of the fos and jun family of proto-oncogenes in osteo- 
blasts (34,51-53), we also examined the effects of these agents 
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FIG. 2. TGFP, and TGF& antagonize basal and 1,25-(OH),D, stimulated OC transcription. ROS 17/2.8 cells were transiently transfected with 
the following osteocalcin promoter-CAT fusion constructs: A) pOCZCAT, -1097/+23, and B) pBgZIICAT -348/+23. Cells were transfected and 
4 h later incubated for 24 h in the absence (control) or presence of 2.5 rig/ml TGFpl (T,), on TGFp2 (T,). These treatment groups were coincubated 
with either vehicle (C, 0) or 1,25-(OH),D, (D, 10-s M). Upper portions of each panel show one representative autoradiogram of a CAT assay. 
The lower portion of each panel are bar graphs representing mean t SD of duplicates and triplicates from three independent transfection 
experiments after quantitation using a p-emission analyzer. CAT activity was corrected for transfection efficiency by luciferase activity. *, 
P < 0.001; **P < 0.005; ***, P < 0.01 us. control; #, P < 0.01, calculated by ANOVA. For details ofP value calculation, see Materials and Methods. 
on AP-1 activity in ROS 17/2.8 osteosarcoma cells. Gel shift 
assays were performed using AP-1 and SP-1 consensus se- 
quences as the probes (Fig. 6). The AI?-1 complex was in- 
creased after incubation with either TGFP or 1,25-(OH),D,, 
although the increase observed with TGFP was more pro- 
nounced than with 1,25-(OH),D,. Combined treatment 
caused a further enhancement of the AP-1 complex. No mod- 
ulation of SP-1 binding activity was observed, which repre- 
sents an internal control for protein quantitation. These find- 
ings indicate selectivity of the TGFP- and 1,25-(OH),D,- 
mediated signaling mechanisms that modulate nuclear 
transcription factor levels. 
VDR protein levels are not rate-limiting for VDRE 
interactions in the presence of TGJ’P and 1,25-(OH)p, 
Because changes in VDR mRNA levels were observed after 
treatment with TGFP,, TGFP,, and 1,25-(OH),D, (Fig. 1), we 
studied the effects of TGFP, and TGFP, in the absence or 
presence of 1,25-(OH),D, on VDR protein levels, as a possible 
mechanism for the inhibitory effects of TGFP on VDR/ RXR 
interactions at the OC and OP VDREs. We investigated the 
effect of TGFP on homologous up-regulation of the VDR by 
Western blot analysis. The results indicate that nuclear VDR 
levels are only detected after treatment with 1,25-(OH),D,, 
and that neither TGFP, nor TGFP, affects the 1,25-(OH),D,- 
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WO. 3. Effects of TGFP, and TGF& on 1,25-(OH),D,-stimulated OP transcription. ROS 17/2.8 cells were transiently transfected with the 
following osteopontin promoter-CAT fusion constructs: A, pOP772CAT, -772/+40; B, pOP552CAT -552/+40. Cells were transfected and 4 h 
later incubated for 24 h in the absence (control) or presence of 2.5 rig/ml TGFPl (T,), or TGFp2 (T,). These treatment groups were coincubated 
with either vehicle (C, 0) or 1,25-(OH),D, (D, 10-s M). Upper portion of each panel shows one representative autoradiogram of a CAT assay. 
The lower portion of each panel are bar graphs representing mean 2 SD of duplicates and triplicates from three independent transfection 
experiments after quantitation using a p-emission analyzer. CAT activity was corrected for transfection effkiency by luciferase activity. *, P 
< 0.001; **, P < 0.005 US. control; #, P < 0.01 (by ANOVA). For details of P value calculation, see Materials and Methods. 
dependent increase in VDR levels (Fig. 7A). Subtle variations 
in the 1,25-(OH),D,-treated lanes appear to reflect similar 
variations in the nonspecific band migrating slower than the 
VDR. The lack of an effect by TGFP on VDR protein levels 
in the presence of 1,25-(OH),D, is further corroborated by 
quantitative analysis of VDR protein using immunoradio- 
metric assays; homologous up-regulation of VDR number in 
nuclear extracts after 1,25-(OH),D, treatment was not af- 
fected by cotreatment with either TGFP, or TGFP, (data not 
shown). Ligand binding assays in whole cell extracts using 
isotopically labeled 1,25-(OH),D, (Fig. 7l3) also demonstrate 
homologous up-regulation of 1,25-(OH),D,-receptor num- 
ber as reflected by a 5-fold increase in ligand binding after 
1,25-(OH),D, treatment. Cotreatment with TGFP (24 h) does 
not affect the homologous up-regulation of 1,25-(OH),D,- 
receptor number in the presence of 1,25-(OH),D,. Thus, the 
evidence presented in Fig. 7 indicates that TGFP inhibition 
of protein/DNA interactions at the VDRE is not the conse- 
quence of a reduction in the level of VDR protein. 
We have found that TGFP alone causes a subtle enhancement 
of VDR levels in whole cell extracts after 24 h of treatment (P 
< 0.05). We have previously reported that the magnitude of this 
response is higher at 6 h after TGFP administration (37). The 
modestly elevated levels of VDR protein after 24 h of TGFP 
treatment therefore may represent a residual, and perhaps per- 
sistent, component of TGFP responsiveness. Our previous ob- 
servation that TGFP enhances VDR levels in whole cell extracts 
as a component of an earlier response (i.e. 6 h) (37) and our 
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FIG. 4. TGFP, and TGFP, inhibit 1,25-(OH),D, enhancement of OC 
VDRE-mediated transcription. ROS 17/2.8 cells were transiently 
transfected with the (WIRE),-tk-luciferase construct. Cells were 
transfected and 4 h later incubated for 24 h in the absence or presence 
of 2.5 rig/ml TGFP, and TGFP,. These treatment groups were coin- 
cubated with either vehicle or 1,25-(OH&D, (lo-@ M). Bar graphs 
represent mean -C SD of luciferase activity. *, P < 0.05; ** P < 0.005 
US. control; #; P < 0.01; ##, P < 0.05 calculated as significance of 
interaction (by ANOVA). For details of P value calculation, see Ma- 
terials and Methods. 
current findings that show that TGFP does not significantly 
influence homologously up-regulated levels of the VDR protein 
at 24 h are both consistent with a complex temporal regulatory 
mechanism for modulation of the VDR levels that may in part 
be compartmentalized. 
Discussion 
In this study we focused on gene regulatory mechanisms 
that control OC and OP expression, which are affected by the 
combined activities of 1,25-(OH),D, and TGFP. The basis of 
our studies is supported by previous studies (36,37) and our 
present findings, which show that TGFP inhibits the 1,25- 
(OH),D,-induced increase of both OC and OP mRNA levels. 
The physiological relevance of TGFP inhibition of the 1,25- 
(OH),D, enhanced expression of osteoblast-related genes is 
exemplified by decreased secretion of the osteocalcin protein, 
a major functional product of osteoblasts. In addition, by 
directly comparing the actions of TGFP, and TGFP,, we show 
that these agents exert identical effects on regulation of OC 
and OP gene expression. This finding is consistent with the 
observation that TGF&- and TGF&mediated cell signaling 
pathways operate via shared TGFP receptor classes (46). 
Using transfection assays with osseous cells and reporter 
gene constructs containing the native OC and OP gene pro- 
moters, we establish that 1,25-(OH),D, related effects of 
TGFP on expression of the OC and OP genes are mediated 
by transcriptional mechanisms. TGFP abrogates 1,25- 
(OH),D, enhancement of OC transcription, which requires 
the presence of the OC VDRE within the promoter. However, 
TGFP also inhibits basal OC transcription in the absence of 
1,25-(OH),D,, which occurs irrespective of the presence of 
VDRE sequences. TGFP repression of basal OC gene tran- 
=P OC VDRE 32P OP VDRE 
T T 
CTD: CT D”D 
FIG. 5. TGFp modulates interactions of endogenous 1,25-(OH)zD,- 
inducible VDR/RXR complexes from ROS 17/2.8 cells. Binding of 
nuclear proteins to the OC VDRE and OP VDRE was analyzed in gel 
mobility shift assays. A, Cells were incubated for 24 h with vehicle (0, 
2.5 rig/ml TGF& (T), lo-'M 1,25-(OH),D, (D) or both (T + D). Nuclear 
protein preparations were incubated with either radiolabeled OC- or 
OP-VDRE. The vitamin D responsive complexes (V) for the OC- and 
OP-VDRE are indicated by the arrowhead. 
scription is mediated by a TGFP response element (TGRE) in 
the proximal promoter of the OC gene (47). Transcriptional 
repression involves binding of AP-1 family members to the 
TGRE (47). Our results show that TGF/3 increases AP-1 bind- 
ing activity both in the presence or absence of 1,25-(OH),D, 
in ROS 17/2.8 cells. Thus, increased levels of AP-1 binding 
may contribute to inhibition of OC gene transcription. 
We note that TGFP also inhibits basal OP gene transcrip- 
tion. This inhibition of OP gene transcription, as monitored 
by reporter gene expression after treatment with TGFP for 24 
h, is not reflected by changes in OP mRNA levels. It appears 
that the TGFP dependent inhibition of OP transcription may 
be compensated by posttranscriptional modulatory events, 
including mRNA processing, transport, and/or stability. Al- 
ternatively, the observed differences between TGFP effects 
on OC transcription and OP mRNA level may reflect dif- 
ferences in the regulation of the endogenous gene and the OF’ 
CAT chimeric reporter gene construct. Noda et al. (16) ob- 
served that TGFP increases OP mRNA levels, concomitant 
with stimulation of OF’ gene transcription, based on results 
from nuclear run-on assays after a 72 h treatment with TGFP. 
This apparent discrepancy in the observed effects of TGFP on 
OP gene expression may relate to differences in experimental 
design, as well as perhaps reflect chronic effects of TGFP on 
cell growth and differentiation of osteoblasts. 
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FIG. 6. Selective enhancement of AP-1 activity by TGF6 and 1,25- 
(OH),D,. Gel mobility shift assays were performed with AP-1 and 
SP-1 consensus oligonucleotides. Nuclear extracts were identical to 
those in Fig. 5. The same abbreviations and symbols are as indicated 
in Fig. 5. The AP-1 complexes (A) represent a composite of het- 
erodimers of the fos and jun family members and are indicated by the 
arrowhead. The triple arrowhead (S) indicates three specific com- 
plexes mediated by the SP-1 family of transcription factors; the upper 
complex represents SP-1, and the two lower complexes are SP-3 re- 
lated proteins. 
We tested the hypothesis that transcriptional repression of 
1,25-(OH),D,-enhanced OC and OP gene expression may be 
achieved by modulating protein/ DNA interactions at the OC 
and OP VDREs. Transcriptional up-regulation of the OC 
gene by 1,25-(OH),D, requires the positive cis-acting VDRE, 
which interacts with VDR/RXR heterodimers in vitro (49, 
54-57) and in vim (58). Our results show that TGFP inhibits 
both 1,25-(OH),D, enhancement of OC VDRE-mediated 
transcription and the 1,25-(OH&Da-dependent induction of 
VDR containing transcription factor complexes interacting 
with the OC- and OP-VDREs. Thus, we propose that TGF/3 
may directly influence OC and OP gene transcription by 
modulating 1,25-(OH),D,-dependent protein/ DNA interac- 
tions at the OC and OP VDREs. This concept is supported by 
previous findings that another polypeptide regulator of OC 
transcription, TNF-a (59), influences 1,25-(OH),D,-regulated 
transcription by modifications of protein/ DNA interactions 
at the VDRE. 
Regulation of the nuclear representation of VDR/RXR het- 
erodimers may occur at multiple levels of control. For ex- 
ample, our results show that VDR mRNA levels are in- 
creased in a 1,25-(OH),D,-dependent manner, which is 
reflected by increased VDR protein levels as monitored by 
0 
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FIG. 7. Homologous up-regulation of VDR protein levels by 1,25- 
(OH&D, is not affected by TGFP. Western blot analysis (A) was 
performed with nuclear proteins from ROS 17/2.8 cells, which were 
separated in a 12% SDS-PAGE gel and transferred to a solid support. 
Detection of VDR levels was performed using the VDR antibody 
IVG8Cll. The abbreviations used are the same as indicated in Figs. 
4 and 5, and the VDR protein (V) is indicated by the arrowhead. The 
subtle variations in the 1,25-(OH),D,-treated lanes appear to reflect 
similar variations in the nonspecific band migrating slower than the 
VDR. Ligand binding assays (B) using 13H11,25-(OH),D, were carried 
out with cytosolic preparations from ROS 17/2.8 cells treated with 
1,25-(OHlaD, and/or TGF-&. The values on the ordinate were cal- 
culated by dividing fmol 13H1 1,25-(OH),D, bound per mg protein by 
the values obtained from untreated cells. Bar-graphs represent mean 
z SD of duplicates from two independent 1,25-(OH),D, ligand binding 
experiments. *, P < 0.05; **, P < 0.0001 us. control. 
Western blot analysis and 1,25-(OH),D, ligand binding as- 
says, as well as induction of VDR/RXR heterodimer inter- 
actions with the VDRE. In coincubation experiments with 
1,25-(OH),D, TGFP reduces the 1,25-(OH),D,-dependent in- 
crease in VDR mRNA, but this decrease is not paralleled by 
a reduction in VDR protein levels. This finding is consistent 
with the observation that stabilization of VDR protein by 
1,25-(OH),D, ligand binding, contributes to the homologous 
up-regulation of the VDR (60). Taken together, these data 
suggest that VDR mRNA levels are not rate-limiting for 
synthesis of VDR protein, and VDR protein levels are not 
rate-limiting for formation of VDR/RXR heterodimers in 
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cells treated with both TGFP and 1,25-(OH),D,. Thus, the 
mechanism by which TGFP reduces VDR / RXR heterodimer 
interactions at VDREs appears to involve posttranslational 
events, p.s. phosphorylation and/or protein/protein inter- 
actions, including effects of TGFP on nuclear availability of 
RXR proteins. 
Phosphorylation of the VDR influences VDRE binding 
activity and transcriptional activation function of VDR/ RXR 
heterodimers (40, 50, 61, 62). Hyperphosphorylation of the 
VDR correlates with decreased VDRE binding activity (50, 
61), and phosphorylation pathways involving protein kinase 
C may posttranslationally modify VDR ill zjiz~o. Because 
TGFP-mediated signal transduction occurs via protein ki- 
nase C (63) and 1,25-(OH)?D, action also involves protein 
kinase C (61, 64), the possibility arises that TGFP may alter 
phosphorylation of the VDR with consequential repression 
of VDR/RXR binding activity and transcriptional activation. 
Accumulating evidence suggests that the functions of 1,25- 
(OH),D, and TGFP in the regulation of bone metabolism and 
parameters of osteoblast differentiation are strongly inter- 
related (34, 36-38). TGFP is capable of increasing 1,25- 
(OH),D, receptor number (65, 37). 1,25-(OH),D, stimulates 
homologous up-regulation of the VDR, which is required for 
the induction of VDR/RXR heterodimers, resulting in the 
transcriptional activation of 1,25-(OH)2D, responsive genes. 
1,25-(OH),D, also stimulates TGFp synthesis and secretion 
by bone cells, as well as enhances TGFP incorporation into 
bone (66,67). The inhibitory effect of TGFP on 1,25-(OH),D,- 
enhancement may provide a negative regulatory loop in the 
action of 1,25-(OH),D,. 
The results presented here suggest that TGFP influences 
OC and OP gene transcription. The effect of TGFP on OC 
gene transcription may occur via a two-pronged mechanism. 
First, TGFP abrogates 1,25-(OH),D, enhancement of OC 
transcription by down-regulating binding of VDR/RXR het- 
erodimers to the OC VDRE. Secondly, TGFP also inhibits OC 
transcription in the presence or absence of 1,25-(OH),D,, 
which occurs via AP-1 binding sites (47, 53), perhaps medi- 
ated by TGFp enhanced levels of AI’-1 proteins. Similarities 
in the inhibitory effect of TGFP on 1,25-(OH),D,-enhanced 
expression of two genes, OC and OP, encoding proteins with 
distinct properties, are consistent with functional linkage of 
these proteins in bone turnover. 
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